Curaleaf Sweetens Aurora Cannabis Bid by 25% in Hostile Takeover Push
Event summary
- Curaleaf increases its offer to acquire Aurora Cannabis to US$5.00 per share, a 25% increase from its initial bid.
- The enhanced offer includes a 33% increase in cash consideration to US$1.00 per share and a 20% increase in the cap price to US$6.00 per share.
- Curaleaf claims support from a significant percentage of Aurora's shareholders despite Aurora's refusal to engage in due diligence.
- The combined entity would operate in 17 countries with over US$1.5 billion in LTM revenue and US$350 million in LTM Adjusted EBITDA.
- Curaleaf extends the expiry time of the offer to December 4, 2026.
The big picture
Curaleaf's aggressive move underscores the ongoing consolidation in the global cannabis sector, as larger players seek to capture economies of scale amid regulatory uncertainty. The enhanced bid reflects both the strategic value of Aurora's international operations and the pressure on Curaleaf to demonstrate its commitment to shareholders. The deal, if completed, would create a dominant player with a pro forma market capitalization exceeding US$3 billion, positioning it to lower its cost of capital and capitalize on future regulatory shifts.
What we're watching
- Regulatory Upside
- How the combined company's scale and international footprint will influence regulatory outcomes in key markets.
- Execution Risk
- Whether Curaleaf can integrate Aurora's operations effectively, particularly given the lack of pre-deal due diligence.
- Shareholder Dynamics
- The pace at which Aurora's shareholders will respond to Curaleaf's enhanced offer amid the ongoing stalemate with the target's board.
Related topics
